Skip to main content
. 2022 Apr 30;14(9):1898. doi: 10.3390/nu14091898

Figure 2.

Figure 2

Nuci improved dyslipidemia, glucose tolerance, and insulin resistance in HFD-fed mice. Seven-weeks male C57BL/6J mice were fed with ND, HFD, HFD supplemented with Nuci and HFD with subcutaneous injection of Lira at 200 μg/kg/day for 12 weeks. Liver function markers including ALT and AST (a), lipid metabolism-related traits including TC, TG HDL-C, and LDL-C (b) and fasting blood glucose (c) were examined. The intraperitoneal glucose tolerance test (IPGTT, (d)) and the intraperitoneal insulin tolerance test (IPITT, (f)) were performed at the 10th week, and area under curves (AUCs) of IPGTT (e) and IPITT (g) were calculated. FINS (h) was determined, and HOMA-IR (i) was calculated accordingly. Serum levels of FGF21 (j) and ZAG (k) were determined by ELISA. Data were presented as mean ± SE, n = 12 in each group. * p < 0.05 vs. the HFD group. In Figure 2d and f, * a, the ND vs. the HFD group; * b the HFD-Nuci vs. the HFD group; * c the HFD-Lira vs. the HFD group.